Our lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (Satoreotide, SSO110), is an antagonist of the somatostatin type 2 receptor (SST2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumors, which currently have few treatment options and a poor prognosis.
Our second most advanced therapeutic product, ATT001 is a novel 123Iodine radiolabeled PARP inhibitor (rPARPi) which is entering Phase 1 clinical study this summer in recurrent glioblastoma patients, an indication of high unmet medical need. Ariceum intends to expand the development of ATT001 into other fast growing PARP expressing tumors.
Through our partnership with UCB Pharma, we are exploring new targets to develop first-in-class radiopharmaceuticals to continue expanding our pipeline.
Ariceum, formally Theragnostics, received FDA approval in Feb 2022 for NephroScan, Kit for the Preparation of Technetium Tc 99m Succimer Injection (99mTc-DMSA).
Please visit our booth, #1849, if you are interested in learning more.